Opthea (OPT) Competitors $3.41 +0.23 (+7.23%) As of 10/8/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock OPT vs. DNLI, SRPT, ETNB, TVTX, ADPT, NTLA, OCUL, ANIP, VERA, and TWSTShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Denali Therapeutics (DNLI), Sarepta Therapeutics (SRPT), 89BIO (ETNB), Travere Therapeutics (TVTX), Adaptive Biotechnologies (ADPT), Intellia Therapeutics (NTLA), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Its Competitors Denali Therapeutics Sarepta Therapeutics 89BIO Travere Therapeutics Adaptive Biotechnologies Intellia Therapeutics Ocular Therapeutix ANI Pharmaceuticals Vera Therapeutics Twist Bioscience Opthea (NASDAQ:OPT) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations. Which has more risk & volatility, OPT or DNLI? Opthea has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Which has better earnings & valuation, OPT or DNLI? Opthea has higher revenue and earnings than Denali Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$30K19,437.00-$162.79MN/AN/ADenali TherapeuticsN/AN/A-$422.77M-$2.80-5.78 Does the media refer more to OPT or DNLI? In the previous week, Denali Therapeutics had 1 more articles in the media than Opthea. MarketBeat recorded 4 mentions for Denali Therapeutics and 3 mentions for Opthea. Opthea's average media sentiment score of 0.82 beat Denali Therapeutics' score of 0.77 indicating that Opthea is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opthea 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is OPT or DNLI more profitable? Opthea's return on equity of 0.00% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Denali Therapeutics N/A -40.79%-36.39% Do insiders & institutionals believe in OPT or DNLI? 56.0% of Opthea shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 3.2% of Opthea shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend OPT or DNLI? Opthea presently has a consensus price target of $1.33, indicating a potential downside of 60.90%. Denali Therapeutics has a consensus price target of $33.50, indicating a potential upside of 107.17%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 2 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.00Denali Therapeutics 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 3.06 SummaryDenali Therapeutics beats Opthea on 8 of the 13 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$583.10M$3.36B$6.15B$10.64BDividend YieldN/A2.29%5.66%4.69%P/E RatioN/A21.3485.9927.64Price / Sales19,437.00488.26628.97141.97Price / CashN/A47.1938.3262.20Price / Book-2.6010.4312.956.79Net Income-$162.79M-$52.40M$3.30B$275.88M7 Day PerformanceN/A4.97%3.69%1.84%1 Month PerformanceN/A17.02%10.68%8.84%1 Year Performance-27.45%34.38%83.35%36.10% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea0.3186 of 5 stars$3.41+7.2%$1.33-60.9%-27.6%$583.10M$30K0.008Gap UpHigh Trading VolumeDNLIDenali Therapeutics4.2821 of 5 stars$15.22-1.3%$33.50+120.1%-39.0%$2.25BN/A-5.44430Analyst ForecastSRPTSarepta Therapeutics4.574 of 5 stars$23.26+2.7%$39.32+69.0%-80.4%$2.21B$1.90B-26.741,372Analyst ForecastGap UpETNB89BIO2.9123 of 5 stars$14.87+0.1%$25.81+73.6%+103.4%$2.20BN/A-4.1240Analyst ForecastTVTXTravere Therapeutics2.2717 of 5 stars$26.13+6.0%$34.20+30.9%+48.2%$2.20B$233.18M-12.81460Analyst ForecastADPTAdaptive Biotechnologies3.0186 of 5 stars$14.47+0.6%$13.22-8.6%+213.0%$2.19B$205.22M-17.65790Analyst ForecastNTLAIntellia Therapeutics3.8906 of 5 stars$20.54+2.9%$27.95+36.1%+44.2%$2.14B$52.86M-4.38600Trending NewsAnalyst ForecastGap UpOCULOcular Therapeutix3.939 of 5 stars$10.97-3.9%$22.13+101.7%+28.4%$1.99B$56.66M-8.57230Analyst ForecastANIPANI Pharmaceuticals3.752 of 5 stars$92.06+2.7%$97.29+5.7%+60.0%$1.95B$614.38M-119.56600Analyst DowngradeVERAVera Therapeutics2.5901 of 5 stars$30.94+2.7%$63.00+103.6%-21.6%$1.92BN/A-8.6440Positive NewsAnalyst ForecastTWSTTwist Bioscience3.8102 of 5 stars$31.85+2.5%$48.90+53.5%-23.1%$1.88B$312.97M-21.97990Trending NewsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies DNLI Alternatives SRPT Alternatives ETNB Alternatives TVTX Alternatives ADPT Alternatives NTLA Alternatives OCUL Alternatives ANIP Alternatives VERA Alternatives TWST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPT) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
